Fed. Circ. Prods Teva On Bid To Revive Nixed Dose Patents
A Federal Circuit panel Tuesday homed in on whether Teva Pharmaceutical s USA Inc.'s invention of three 40-milligram injections per week for its multiple sclerosis drug Copaxone was obvious in light...To view the full article, register now.
Already a subscriber? Click here to view full article